Hepion Pharmaceuticals to Participate in the H.C. Wainwright 5th Annual NASH Investor Conference

Rhea-AI Summary

Hepion Pharmaceuticals (NASDAQ:HEPA), a clinical-stage biopharmaceutical company specializing in AI-driven drug development, announced that its CMO, Dr. Todd Hobbs, will present at the H.C. Wainwright 5th Annual NASH Investor Conference on October 12, 2021, at 4:00 p.m. ET. This virtual presentation will be accessible live and archived on the company's website.

The lead drug candidate, CRV431, is in clinical development for the treatment of NASH and aims to improve outcomes in liver disease. Hepion's proprietary platform, AI-POWR™, is designed to identify optimal NASH patient responses.

EDISON, N.J., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”) and liver disease, today announced that its CMO, Dr. Todd Hobbs, will present at the H.C. Wainwright 5th Annual NASH Investor Conference on Tuesday, October 12, 2021, at 4:00 p.m. Eastern Time.

The virtual presentation will be broadcast live and archived on the Company's website at www.hepionpharma.com under "Events" in the “Investors” section.

About Hepion Pharmaceuticals

The Company's lead drug candidate, CRV431, is a potent inhibitor of cyclophilins, which are involved in many disease processes. CRV431 is currently in clinical-phase development for the treatment of NASH, with the potential to play an important role in the overall treatment of liver disease - from triggering events through to end-stage disease. CRV431 has been shown to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH; and has demonstrated antiviral activities towards HBV, HCV, and HDV through several mechanisms, in nonclinical studies.

Hepion has created a proprietary AI platform, called AI-POWR™, which stands for Artificial Intelligence - Precision Medicine; Omics (including genomics, proteomics, metabolomics, transcriptomics, and lipidomics); World database access; and Response and clinical outcomes. Hepion intends to use AI-POWR™ to help identify which NASH patients will best respond to CRV431, potentially shortening development timelines and increasing the delta between placebo and treatment groups. In addition to using AI-POWR™ to drive its ongoing NASH clinical development program, Hepion intends to use the platform to identify additional potential indications for CRV431 to expand the company's footprint in the cyclophilin inhibition therapeutic space.

Forward Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimated,” and “intend,” among others. These forward-looking statements are based on Hepion Pharmaceuticals’ current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; risks associated with delays, increased costs and funding shortages caused by the COVID-19 pandemic; uncertainties with respect to lengthy and expensive clinical trials, that results of earlier studies and trials may not be predictive of future trial results; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any drug candidates under development, there are significant risks in the development, regulatory approval, and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful, or that any product will receive regulatory approval for any indication or prove to be commercially successful. Hepion Pharmaceuticals does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in Hepion Pharmaceuticals’ Form 10-K for the year ended December 31, 2020, and other periodic reports filed with the Securities and Exchange Commission.

For further information, please contact:

Stephen Kilmer
Hepion Pharmaceuticals Investor Relations
Direct: (646) 274-3580
skilmer@hepionpharma.com  

FAQ

What is the date and time of the Hepion Pharmaceuticals presentation at the NASH Investor Conference?

The presentation is scheduled for October 12, 2021, at 4:00 p.m. Eastern Time.

Where can I watch the Hepion Pharmaceuticals presentation?

The presentation will be available live and archived on the Hepion Pharmaceuticals website under the 'Events' section.

What is CRV431 and its significance in liver disease treatment?

CRV431 is Hepion's lead drug candidate, currently in clinical development for treating NASH, aiming to reduce liver fibrosis and cancer risk.

What is the purpose of the AI-POWR™ platform developed by Hepion Pharmaceuticals?

AI-POWR™ is designed to identify which NASH patients will best respond to CRV431, potentially shortening development timelines.

What are the main challenges facing Hepion Pharmaceuticals in drug development?

Challenges include competition, financing needs, clinical trial uncertainties, and regulatory approvals.